Market Cap 5.51B
Revenue (ttm) 376.57M
Net Income (ttm) -77.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -20.63%
Debt to Equity Ratio 0.03
Volume 1,459,900
Avg Vol 1,769,976
Day's Range N/A - N/A
Shares Out 62.27M
Stochastic %K 18%
Beta 2.11
Analysts Strong Sell
Price Target $104.00

Company Profile

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing,...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 800 719 0671
Address:
681 Gateway Boulevard, South San Francisco, United States
ajmrtxl
ajmrtxl Jul. 28 at 4:51 PM
$TWST 's latest data on SqueezeFinder
0 · Reply
ajmrtxl
ajmrtxl Jul. 28 at 4:34 PM
$TWST 's latest data on SqueezeFinder
0 · Reply
11thestate
11thestate Jul. 27 at 3:42 PM
The court has approved the $17.05M $TWST investor settlement. The case centered on allegations that Twist presented a stronger picture of its manufacturing process and margins than reality. After a short-seller report raised concerns about production issues, quality problems, and financial reporting, $TWST fell 20% in 2022. With the settlement now approved, eligible investors may be able to submit a claim: https://11th.com/cases/twist-investor-settlement
0 · Reply
B2iDigital
B2iDigital Jul. 24 at 9:57 PM
eXoZymes (Nasdaq: $EXOZ ) is among the first projects selected for the inaugural U.S. Department of Energy (DOE) Genesis Mission, a nationwide initiative bringing together national laboratories, universities, companies, and nonprofit organizations to accelerate scientific discovery. eXoZymes will work with Lawrence Berkeley National Laboratory to build AI-powered digital twins for its cell-free biomanufacturing platform. eXoZymes is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes The project extends the company’s AI work from enzyme engineering into manufacturing: • With Berkeley Lab, eXoZymes will develop hybrid digital twins that combine enzyme kinetics, reactor physics, and machine learning to identify optimal operating conditions before lab validation • The award provides access to the DOE Genesis Mission Platform: advanced AI models, AI agents, and high-performance computing • Subject to DOE award negotiations, the project is expected to carry about $747,000 in total funding, including about $147,000 for eXoZymes “We believe the next generation of biomanufacturing will be built at the intersection of artificial intelligence and digital insights into biology,” said Michael Heltzen, Chief Executive Officer of eXoZymes. Read the full release: https://exozymes.com/blog/genesis-mission-2026 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
xX_Rothschild_Xx
xX_Rothschild_Xx Jul. 24 at 9:04 PM
$TWST got me feelin
0 · Reply
RemitTekram
RemitTekram Jul. 24 at 12:21 PM
$TWST You always have to knock the barrier a few times to become a triple digit stock.
0 · Reply
B2iDigital
B2iDigital Jul. 23 at 4:01 PM
eXoZymes (Nasdaq: $EXOZ ) frames itself as a repeatable engine for unlocking molecule classes. In a Webull webinar, Chief Commercial Officer Damien Perriman put cannabinoids forward as the next class after NCT. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 "This is not a single product company. It's a repeatable system for unlocking entire classes of molecules," Perryman told investors. Also from the presentation: • NCT is the first proof point and cannabinoids are the second, with cannabinoid receptors present on nearly every cell in the body • That reach spans metabolic, inflammatory, and neurological conditions, where access to rare cannabinoids has long been the bottleneck • eXoZymes says it can now produce rare and entirely new cannabinoids without intoxicating components, optimized toward specific therapeutic objectives Watch the full webinar: https://youtu.be/OmH3TaaMT20 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
RemitTekram
RemitTekram Jul. 22 at 1:59 AM
$TWST Well done Bulls!!
0 · Reply
11thestate
11thestate Jul. 21 at 3:38 PM
When we see a stock like this, we know how many damaged investors are out there. $TWST investors you might be surprised, but you actually have a chance to recover your losses. Don’t miss it: https://11th.com/cases/twist-investor-settlement
0 · Reply
handmedown1
handmedown1 Jul. 20 at 5:40 PM
$CRSP wish crispy had that $TWST energy
0 · Reply
Latest News on TWST
Twist Bioscience files automatic mixed securities shelf

2026-06-18T20:15:47.000Z - 5 weeks ago

Twist Bioscience files automatic mixed securities shelf


Ozempic Linked To Lower Risk Of Violence In New Study

Jun 17, 2026, 11:45 AM EDT - 6 weeks ago

Ozempic Linked To Lower Risk Of Violence In New Study

AZN LLY NVO


Twist Bioscience initiated with a Buy at Canaccord

2026-06-15T09:45:05.000Z - 6 weeks ago

Twist Bioscience initiated with a Buy at Canaccord


Twist Bioscience Slides: Corporate presentation

Jun 2, 2026, 7:00 AM EDT - 2 months ago

Twist Bioscience Slides: Corporate presentation


Twist Bioscience Transcript: Investor Day 2026

May 21, 2026, 2:00 PM EDT - 2 months ago

Twist Bioscience Transcript: Investor Day 2026


Twist Bioscience Slides: FY 2026

May 21, 2026, 2:00 PM EDT - 2 months ago

Twist Bioscience Slides: FY 2026


Twist Bioscience Earnings Call Transcript: Q2 2026

May 4, 2026, 8:00 AM EDT - 3 months ago

Twist Bioscience Earnings Call Transcript: Q2 2026


Twist Bioscience Earnings release: Q2 2026

May 4, 2026, 8:00 AM EDT - 3 months ago

Twist Bioscience Earnings release: Q2 2026


Twist Bioscience Slides: Q2 2026

May 4, 2026, 8:00 AM EDT - 3 months ago

Twist Bioscience Slides: Q2 2026


Twist Bioscience Quarterly report: Q2 2026

May 4, 2026, 8:00 AM EDT - 3 months ago

Twist Bioscience Quarterly report: Q2 2026


Twist Bioscience to Present at Upcoming Investor Conferences

Feb 18, 2026, 8:00 AM EST - 5 months ago

Twist Bioscience to Present at Upcoming Investor Conferences


Twist Bioscience Slides: Corporate presentation

Feb 17, 2026, 7:00 AM EST - 5 months ago

Twist Bioscience Slides: Corporate presentation


Twist Bioscience Transcript: AGM 2026

Feb 5, 2026, 10:00 AM EST - 6 months ago

Twist Bioscience Transcript: AGM 2026


Twist Bioscience Earnings Call Transcript: Q1 2026

Feb 2, 2026, 8:00 AM EST - 6 months ago

Twist Bioscience Earnings Call Transcript: Q1 2026


Twist Bioscience Quarterly report: Q1 2026

Feb 2, 2026, 8:00 AM EST - 6 months ago

Twist Bioscience Quarterly report: Q1 2026


Twist Bioscience Earnings release: Q1 2026

Feb 2, 2026, 8:00 AM EST - 6 months ago

Twist Bioscience Earnings release: Q1 2026


Twist Bioscience Slides: Q1 2026

Feb 2, 2026, 8:00 AM EST - 6 months ago

Twist Bioscience Slides: Q1 2026


Twist Bioscience Proxy statement: Proxy Filing

Jan 6, 2026, 7:00 AM EST - 7 months ago

Twist Bioscience Proxy statement: Proxy Filing


Can Twist Bioscience Drop More?

Nov 17, 2025, 9:25 AM EST - 9 months ago

Can Twist Bioscience Drop More?


Twist Bioscience Earnings Call Transcript: Q4 2025

Nov 14, 2025, 8:00 AM EST - 9 months ago

Twist Bioscience Earnings Call Transcript: Q4 2025


Twist Bioscience Annual report: Q4 2025

Nov 14, 2025, 8:00 AM EST - 9 months ago

Twist Bioscience Annual report: Q4 2025


Twist Bioscience Earnings release: Q4 2025

Nov 14, 2025, 8:00 AM EST - 9 months ago

Twist Bioscience Earnings release: Q4 2025


Twist Bioscience Slides: Q4 2025

Nov 14, 2025, 8:00 AM EST - 9 months ago

Twist Bioscience Slides: Q4 2025


Twist Bioscience Slides: FY 2025

Sep 9, 2025, 9:40 AM EDT - 11 months ago

Twist Bioscience Slides: FY 2025


Twist Bioscience Collaborates with Synthetic Design Lab

Sep 2, 2025, 8:00 AM EDT - 11 months ago

Twist Bioscience Collaborates with Synthetic Design Lab


Twist Bioscience Earnings Call Transcript: Q3 2025

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Earnings Call Transcript: Q3 2025


Twist Bioscience Quarterly report: Q3 2025

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Quarterly report: Q3 2025


Twist Bioscience Earnings release: Q3 2025

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Earnings release: Q3 2025


Twist Bioscience Slides: Q3 2025

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Slides: Q3 2025


Twist Bioscience Slides: Corporate Presentation

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Twist Bioscience Slides: Corporate Presentation


Twist Bioscience and Ginkgo Bioworks Revise Collaboration

May 8, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience and Ginkgo Bioworks Revise Collaboration

DNA


Twist Bioscience Earnings Call Transcript: Q2 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Earnings Call Transcript: Q2 2025


Twist Bioscience Quarterly report: Q2 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Quarterly report: Q2 2025


Twist Bioscience Earnings release: Q2 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Earnings release: Q2 2025


Twist Bioscience Slides: Q2 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Slides: Q2 2025


Twist Bioscience Earnings Call Transcript: Q1 2025

Feb 3, 2025, 8:00 AM EST - 1 year ago

Twist Bioscience Earnings Call Transcript: Q1 2025


Twist Bioscience Quarterly report: Q1 2025

Feb 3, 2025, 8:00 AM EST - 1 year ago

Twist Bioscience Quarterly report: Q1 2025


Twist Bioscience Earnings release: Q1 2025

Feb 3, 2025, 8:00 AM EST - 1 year ago

Twist Bioscience Earnings release: Q1 2025


Twist Bioscience Slides: Q1 2025

Feb 3, 2025, 8:00 AM EST - 1 year ago

Twist Bioscience Slides: Q1 2025


Twist Bioscience Proxy statement: Proxy Filing

Jan 6, 2025, 7:00 AM EST - 1 year ago

Twist Bioscience Proxy statement: Proxy Filing


Twist Bioscience Proxy statement: Proxy Filing

Dec 26, 2024, 7:00 AM EST - 1 year ago

Twist Bioscience Proxy statement: Proxy Filing


Twist Bioscience Earnings Call Transcript: Q4 2024

Nov 18, 2024, 8:00 AM EST - 1 year ago

Twist Bioscience Earnings Call Transcript: Q4 2024


Twist Bioscience Annual report: Q4 2024

Nov 18, 2024, 8:00 AM EST - 1 year ago

Twist Bioscience Annual report: Q4 2024


Twist Bioscience Earnings release: Q4 2024

Nov 18, 2024, 8:00 AM EST - 1 year ago

Twist Bioscience Earnings release: Q4 2024


Twist Bioscience Slides: Q4 2024

Nov 18, 2024, 8:00 AM EST - 1 year ago

Twist Bioscience Slides: Q4 2024


ajmrtxl
ajmrtxl Jul. 28 at 4:51 PM
$TWST 's latest data on SqueezeFinder
0 · Reply
ajmrtxl
ajmrtxl Jul. 28 at 4:34 PM
$TWST 's latest data on SqueezeFinder
0 · Reply
11thestate
11thestate Jul. 27 at 3:42 PM
The court has approved the $17.05M $TWST investor settlement. The case centered on allegations that Twist presented a stronger picture of its manufacturing process and margins than reality. After a short-seller report raised concerns about production issues, quality problems, and financial reporting, $TWST fell 20% in 2022. With the settlement now approved, eligible investors may be able to submit a claim: https://11th.com/cases/twist-investor-settlement
0 · Reply
B2iDigital
B2iDigital Jul. 24 at 9:57 PM
eXoZymes (Nasdaq: $EXOZ ) is among the first projects selected for the inaugural U.S. Department of Energy (DOE) Genesis Mission, a nationwide initiative bringing together national laboratories, universities, companies, and nonprofit organizations to accelerate scientific discovery. eXoZymes will work with Lawrence Berkeley National Laboratory to build AI-powered digital twins for its cell-free biomanufacturing platform. eXoZymes is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes The project extends the company’s AI work from enzyme engineering into manufacturing: • With Berkeley Lab, eXoZymes will develop hybrid digital twins that combine enzyme kinetics, reactor physics, and machine learning to identify optimal operating conditions before lab validation • The award provides access to the DOE Genesis Mission Platform: advanced AI models, AI agents, and high-performance computing • Subject to DOE award negotiations, the project is expected to carry about $747,000 in total funding, including about $147,000 for eXoZymes “We believe the next generation of biomanufacturing will be built at the intersection of artificial intelligence and digital insights into biology,” said Michael Heltzen, Chief Executive Officer of eXoZymes. Read the full release: https://exozymes.com/blog/genesis-mission-2026 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
xX_Rothschild_Xx
xX_Rothschild_Xx Jul. 24 at 9:04 PM
$TWST got me feelin
0 · Reply
RemitTekram
RemitTekram Jul. 24 at 12:21 PM
$TWST You always have to knock the barrier a few times to become a triple digit stock.
0 · Reply
B2iDigital
B2iDigital Jul. 23 at 4:01 PM
eXoZymes (Nasdaq: $EXOZ ) frames itself as a repeatable engine for unlocking molecule classes. In a Webull webinar, Chief Commercial Officer Damien Perriman put cannabinoids forward as the next class after NCT. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 "This is not a single product company. It's a repeatable system for unlocking entire classes of molecules," Perryman told investors. Also from the presentation: • NCT is the first proof point and cannabinoids are the second, with cannabinoid receptors present on nearly every cell in the body • That reach spans metabolic, inflammatory, and neurological conditions, where access to rare cannabinoids has long been the bottleneck • eXoZymes says it can now produce rare and entirely new cannabinoids without intoxicating components, optimized toward specific therapeutic objectives Watch the full webinar: https://youtu.be/OmH3TaaMT20 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
RemitTekram
RemitTekram Jul. 22 at 1:59 AM
$TWST Well done Bulls!!
0 · Reply
11thestate
11thestate Jul. 21 at 3:38 PM
When we see a stock like this, we know how many damaged investors are out there. $TWST investors you might be surprised, but you actually have a chance to recover your losses. Don’t miss it: https://11th.com/cases/twist-investor-settlement
0 · Reply
handmedown1
handmedown1 Jul. 20 at 5:40 PM
$CRSP wish crispy had that $TWST energy
0 · Reply
StageAnalysis
StageAnalysis Jul. 19 at 9:35 AM
New Blog Post: US Stocks Watchlist There are 20 stocks highlighted from the weekends US stocks watchlist scans – $DXCM, $BAND, $TWST https://www.stageanalysis.net/blog/1398096/us-stocks-watchlist-20-july-2026
0 · Reply
B2iDigital
B2iDigital Jul. 17 at 9:10 PM
A platform that works in the lab is not yet a business. In a Webull webinar, eXoZymes (Nasdaq: $EXOZ ) pointed to a scale-up run it says clears that bar. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 Perryman framed the milestone directly: "Many technologies work in the lab, but many also fail at scale. What we've demonstrated here is that the system translates from concept to industrial conditions, and that's what turns this from a science into a viable business." The webinar detailed the run: • The company ran a 100-liter pilot at the end of last year, reporting 99% conversion of raw material to target product and 99.6% purity • The run took place at a third party after eXoZymes tech-transferred its process, operating conditions, and enzyme cascades • Management called this an operational process rather than a theoretical one, and an inflection point for investors Watch the full webinar: https://youtu.be/OmH3TaaMT20 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
staydowngetdown
staydowngetdown Jul. 17 at 11:33 AM
$TWST she’s selling….
0 · Reply
_ivan
_ivan Jul. 16 at 6:48 AM
0 · Reply
11thestate
11thestate Jul. 15 at 12:32 PM
Imagine buying $TWST at its peak, only to watch it crash like this and then finding out there’s a way to get some money back. To all $TWST investors out there, we’ve got some important news: a $17 million investor settlement is now open for claims from shareholders who purchased shares between 2018 and 2022. You can check if you’re eligible and claim your share:https://11th.com/cases/twist-investor-settlement
0 · Reply
B2iDigital
B2iDigital Jul. 14 at 5:15 PM
eXoZymes (Nasdaq: $EXOZ ) is targeting metabolic dysfunction a layer deeper than appetite. In a recent Webull webinar, Chief Commercial Officer Damien Perriman walked investors through NCT, the company's first proof point. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 "It is fundamentally different from GLP-1 drugs," Perryman said. "GLP-1s reduce appetite, whereas NCT and its activation of HNF4 alpha improves mitochondrial biogenesis and mitochondrial activity, essentially improving how the body burns fat." From the same segment: • NCT activates HNF4 alpha, a master metabolic control switch, rather than acting on a single downstream symptom • In controlled preclinical models on identical diets, eXoZymes reported 30% to 40% less weight gain in the mouse population • The company also observed improved mitochondrial function and reduced liver fat, consistent with hitting a central regulatory pathway Watch the full webinar: https://youtu.be/OmH3TaaMT20 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
handmedown1
handmedown1 Jul. 14 at 5:04 PM
$CRSP look at $TWST ..... wow ... crsp is just garbage
0 · Reply
FoxMarketEye
FoxMarketEye Jul. 10 at 2:26 PM
Top 10 largest positions currently held in Cathie Wood’s ARKK portfolio: $SHOP - 4% $SPCX - 4% $COIN - 4% $TWST - 4% $RBLX - 3% ARKK’s strategy is simple: find companies targeting massive markets before mainstream adoption arrives.
0 · Reply
stu4
stu4 Jul. 10 at 11:30 AM
$HROW $QURE $REPL $SLS $TWST So F OFF @ezimon …little Chris , can’t take the truth ..move along No, whimps block !!!! Another loser , similar to Matt Kapushit
2 · Reply
stu4
stu4 Jul. 10 at 10:31 AM
$HROW $QURE $REPL $SLS $TWST of course when the CEO continues to sell, creates hype of his HD , and never buying shares, one could decide to SHORT !!!
2 · Reply
stu4
stu4 Jul. 9 at 11:25 PM
$HROW $QURE $REPL $SLS $TWST another loser that fcuks with dollar stocks…cashless a hole
0 · Reply
MOOSEN
MOOSEN Jul. 9 at 6:12 PM
$HROW $QURE $REPL $SLS $TWST THIS DUDE FOR REAL?
2 · Reply